Changeflow GovPing Pharma & Drug Safety Methods of Treating Locally Advanced or Metasta...
Routine Notice Added Final

Methods of Treating Locally Advanced or Metastatic Breast Cancers Using PD-1 Axis Binding Antagonists and Taxanes

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3310815A1, filed by F. Hoffmann-La Roche AG, covering methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists in combination with taxanes. Inventor is Daniel S. Chen. The publication includes IPC classifications covering therapeutic antibodies, antineoplastic compositions, and designated states for national phase entry.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published patent application EP3310815A1 for methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists combined with taxanes, filed by F. Hoffmann-La Roche AG with inventor Daniel S. Chen. The application covers therapeutic uses of PD-1/PD-L1 inhibitors with taxane chemotherapy.

Competitors developing breast cancer treatments involving PD-1 pathway inhibitors should review the scope of these patent claims for freedom-to-operate considerations or potential design-around opportunities.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

Publication EP3310815A1 Kind: A1 Apr 08, 2026

Applicants

F. Hoffmann-La Roche AG

Inventors

CHEN, Daniel, S.

IPC Classifications

C07K 16/28 20060101AFI20251110BHEP A61K 31/337 20060101ALI20251110BHEP A61P 35/04 20060101ALI20251110BHEP A61K 39/00 20060101ALI20251110BHEP A61K 31/519 20060101ALI20251110BHEP A61P 35/00 20060101ALI20251110BHEP A61P 37/02 20060101ALI20251110BHEP A61P 37/04 20060101ALI20251110BHEP A61P 43/00 20060101ALI20251110BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3310815A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Therapeutic compound development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!